Should Allergan's controversial patent deal with the Saint Regis Mohawk Tribe hold up and delay generic competition for Restasis until 2024, the deal would cost the U.S. health care system $10.7 billion in lost savings, group purchasing organization Vizient estimates. But the Allergan CEO says his company's move to dodge the inter partes review (IPR) process, which the company says is unfair, does not mean generics will necessarily be delayed until 2024 -- when the drug's Orange Book-listed patents expire...